Answers are grounded in this paper and cite their sources.
Traditional thrombolytic drugs such as urokinase and tissue plasminogen activator for vascular blockage remain large challenging due to their off-target side effects, low bioavailability and limited penetration abilities in blood clots, leading to the limited therapeutic effect. Considering the rapid developments of nanotechnology, the exploration of an innovative nanomaterials-based thrombolytic strategy for treating venous thromboembolism is highly demanded. Here, we present a polydopamine nanoparticles integrated microneedle patch for near-infrared-II light triggered thrombolysis in vitro and in vivo. Polydopamine nanoparticles with the near-infrared-II photothermal conversion performance were prepared at room temperature in the dark, and then were integrated into microneedle patch using the common polydimethylsiloxane microneedle mold. Polydopamine nanoparticles integrated microneedle patch not only showed good mechanical performance to easily insert into the skin without breaking, but also showed outstanding near-infrared-II photothermal conversion abilities. In vitro thrombolytic results proved that polydopamine nanoparticles integrated microneedle patch could induce the blood clot lysis in vitro under 1064 nm light irradiation for 5 min. Also, this microneedle patch showed effective thrombolysis effect by near-infrared-II light induced local overheating against the femoral vein thrombi model of female BALB/c mice. Overall, this microneedle patch has the great potential to treat venous thromboembolism.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: